Amyris Inc. (AMRS) Major Shareholder (Mauritius) Pte Ltd Maxwell Sells 427,904 Shares
Amyris Inc. (NASDAQ:AMRS) major shareholder (Mauritius) Pte Ltd Maxwell sold 427,904 shares of the business’s stock in a transaction dated Friday, November 11th. The stock was sold at an average price of $0.81, for a total transaction of $346,602.24. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
(Mauritius) Pte Ltd Maxwell also recently made the following trade(s):
- On Tuesday, November 8th, (Mauritius) Pte Ltd Maxwell sold 333,811 shares of Amyris stock. The stock was sold at an average price of $0.82, for a total transaction of $273,725.02.
- On Friday, November 4th, (Mauritius) Pte Ltd Maxwell sold 2,611,233 shares of Amyris stock. The stock was sold at an average price of $0.89, for a total transaction of $2,323,997.37.
- On Monday, October 17th, (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of Amyris stock. The stock was sold at an average price of $0.83, for a total transaction of $1,909,000.00.
Shares of Amyris Inc. (NASDAQ:AMRS) opened at 0.7972 on Tuesday. The stock’s 50 day moving average is $0.81 and its 200 day moving average is $0.57. The firm’s market capitalization is $198.65 million. Amyris Inc. has a 12 month low of $0.31 and a 12 month high of $1.81.
Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $26.50 million for the quarter, compared to analyst estimates of $33.61 million. During the same quarter last year, the company posted ($0.23) earnings per share. The business’s revenue for the quarter was up 208.1% compared to the same quarter last year. Equities research analysts forecast that Amyris Inc. will post ($0.25) earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. acquired a new position in Amyris during the first quarter worth approximately $269,000. KBC Group NV raised its position in Amyris by 330.1% in the third quarter. KBC Group NV now owns 329,101 shares of the company’s stock worth $191,000 after buying an additional 252,589 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares in the last quarter. 35.75% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have recently issued reports on AMRS. Zacks Investment Research downgraded shares of Amyris from a “buy” rating to a “hold” rating in a report on Monday, September 5th. Singular Research restated a “buy” rating and set a $2.80 price objective on shares of Amyris in a report on Wednesday, September 28th.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.